Abstract: A transdermal absorptive drug formulation containing 3-isobutyryl-2-isopropylpyrazolo [1,5-a ]pyridine as active ingredient effective for bronchial asthma and cerebrovascular disorder is provided. The formulation affords excellent sustained releasing and long acting characteristics with substantially reduced side-effects such as nausea and vomitting.

Abstract: A therapeutic pharmaceutical composition containing 3,4,5-trimethoxy-N-3-piperidylbenzamide (troxipide) as an active ingredient for gastritis in admixture with an inert pharmaceutical carrier. The composition may be administered orally in the forms of tablets, capsules, granules and fine granules.

Abstract: Freeze-dried pharmaceutical preparation containing antibacterial quinolinecarboxylic acid derivatives are provided. These preparations are characterized by their stability against light and heat and have rapid solubility.

Abstract: A controlled-release pharmaceutical preparation of 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine. The controlled-release preparation is in the form of powder or granule containing 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine, coated with medically non-active substance or in the form of rectal suppository containing 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine. Further the controlled-release is prepared by implanting 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine in fatty materials, or granulating it and coating the resultant particles with medically non-active substance.

Abstract: An indole derivative represented by the general formula (I) ##STR1## wherein R is hydrogen, lower alkyl having 1 to 6 carbons, carboxymethyl, or substituted or unsubstituted aralkyl; R.sup.1, R.sup.2, R.sup.3, and R.sup.4 may be the same with or different from each other and are hydrogen, halogen, lower alkyl having 1 to 6 carbons, lower alkoxy having 1 to 6 carbons, acyl, substituted or unsubstituted amino, nitro, hydroxy, acyloxy, substituted or unsubstituted aralkyl, substituted or unsubstituted aryloxy, or substituted or unsubstituted aralkyloxy, or a combination of R.sup.2 and R.sup.3 may be methylenedioxy;R.sup.5 is hydrogen, lower alkyl having 1 to 6 carbons, or substituted or unsubstituted aralkyl; R and R.sup.4, or R.sup.1 and R.sup.5 may form together a six-membered ring constituted of methylene chains which may contain a heteroatom;R.sup.6 and R.sup.

Abstract: An ameliorating agent for dysmnesia, comprising as an effective component or components at least one of pyrazolo[1,5-a]pyridine derivatives represented by the general formula: ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen or a lower alkyl of 1-4 carbons, R.sup.3 is hydrogen or a lower alkyl of 1-3 carbons or a lower alkoxy of 1-3 carbons.

Abstract: This invention relates to new and useful 2,6-dimethyl-4-(pyrazolo[1,5-a]pyridin-3-yl)-1,4-dihydropyridine-3,5-dicar boxylate derivatives of the following formula: ##STR1## and pharmaceutically acceptable salts thereof, having potent promoting activity of some antitumor agents against various kinds of tumor cells including multiple drug resistant tumor cells.

Abstract: Novel anti-rheumatic agent containing 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine as an active ingredient.

Abstract: New compounds effective as antibacterial agent are disclosed. These new compounds include 8-[4-(4-aminobenzyl)-1-piperazinyl]-9-fluoro-6,7-dihydro-5-methyl-1-oxo-1H ,5H-benzo[ij]quinolizine-2-carboxylic acid, hydrates and acid addition salts thereof, and possess superior activities against gram-negative and gram-positive of aerobicbacteria.

Abstract: Process for the preparation of useful antimicorbial agents, 1-substituted-6-fluoro-7-(1-piperazinyl or 4-substituted-1-piperazinyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acids having the chemical structure [IV], ##STR1## wherein R.sub.1 is ethyl or vinyl group, andR.sub.4 is ##STR2## (R.sub.3 is hydrogen atom or lower alkyl group).

Abstract: This invention relates to new compounds of value as antibacterial agents. More particularly, it relates to quinoline carboxylic acid derivatives, the hydrates and the acid or alkali addition salts thereof.

Abstract: This invention relates to new compounds of value as antibacterial agent. More particularly, it relates to quinoline carboxylic acid derivatives, the hydrates and the salts thereof.

Abstract: This invention relates to new compounds of value as antibacterial agent. More particularly, it relates to piperazinyl derivatives of quinoline carboxylic acids, the hydrates, and the acid addition salts thereof.

Abstract: 1-(3-Phenylpropyl)-4-furoylpiperazine represented by the following general formula (I), ##SPC1##(wherein: R.sub.1 and R.sub. 2, which may be the same or different, each represents a hydrogen atom or a lower alkyl group containing 1 to 4 carbon atoms; R.sub.3 represents a hydrogen atom, a halogen atom, a lower alkyl group containing 1 to 4 carbon atoms, or a lower alkoxy groups containing 1 to 4 carbon atoms; R.sub.4 and R.sub.5, which may be the same or different, each represents a hydrogen atom or a lower alkyl group containing 1 to 4 carbon atoms), and pharmaceutically acceptable addition salts thereof.

Abstract: A compound of the formula (I), ##SPC1##and the non-toxic acid addition salts thereof are disclosed. These compounds and salts are useful as therapeutic agents for allergic diseases.

Abstract: A process for preparing a pyrogen-free plasma substitute consisting of treating hydroxyethyl starch having a DS of 0.5 - 0.6 (preferably 0.55) and an intrinsic viscosity of 0.28 - 0.30 with an acid to lower the molecular weight; adjusting it to the desired hydroxyethyl starch having a DS of 0.55 and an intrinsic viscosity of 0.08- 0.14; adding a depyrogen reagent, such as Raney-nickel to it, if necessary, obtaining an isotonic aqueous solution containing 6% of hydroxyethyl starch and other various salts, preferably, adding sodium chloride (0.5%), potassium chloride (0.03%), calcium chloride dihydrate (0.02%), sodium lactate (0.224%), and glucose (1%)(W/V%) to 6% hydroxyethyl starch solution; and then adjusting the pH of the obtained iostonic aqueous solution to 6.2 .+-. 0.5.

Abstract: The present invention relates to a valuable medicament for oral administration containing N-benzenesulfonyl-.beta.-alanine hydrazide as an effective ingredient. The drug of this invention is useful, as an immunosuppressive agent, for suppression of so-called autoimmune diseases such as nephrotic syndromes, rheumatoid arthritis and systemic lupus erythematosus etc.Furthermore, it may be possible to decrease or withdraw from dosing of corticosteroid by the use of KH-125 in a patient who has long been treated with that hormone.